Bridged Polycyclic Compounds for Oral Coatings
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendrimer synthesis methods are inefficient and prone to defects, and existing dental materials fail to effectively prevent and treat oral diseases such as gingivitis and periodontal disease, requiring a more effective and affordable solution for maintaining oral health.
Innovation Solution
Development of bridged polycyclic compounds with two or more cyclic groups, capable of attaching multiple pharmaceutically active agents, forming antimicrobial coatings for oral surfaces, and providing long-term protection against tartar build-up, gingivitis, and halitosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendrimers are used as carrier agents for antiviral agents, then the intracellular amount of drug is increased, but the synthesis becomes time-consuming and expensive with repeated purifications required
Solution Approach 1:
The patent segments the complex dendrimer structure into simpler modular components - specifically using bridged polycyclic compounds as core structures with attachable functional groups. This segmentation allows for easier synthesis without requiring repeated purifications, while still maintaining the ability to deliver drugs intracellularly through the preserved dendritic architecture.
Solution Approach 2:
The invention replaces expensive, time-consuming dendrimer synthesis with more affordable, simpler bridged polycyclic compound synthesis. The patent uses readily available starting materials and straightforward chemical reactions that do not require extensive purification steps, making the process economically viable and time-efficient while achieving the same drug delivery function.
2Stability of the object's composition
If dendrimers are synthesized using divergent or convergent methods, then the molecular structure is formed, but defects in the molecular structure occur and other molecules become trapped within the spaces
Solution Approach 1:
Instead of building up complex dendrimer structures from simple units (which causes defects and trapped molecules), the patent inverts the approach by using pre-formed bridged polycyclic compounds with defined cavity structures. These compounds naturally possess hollow spaces that can accommodate drug molecules without trapping unrelated molecules, eliminating the structural defects inherent in traditional dendrimer synthesis.
3Ease of operation
If existing dental materials are used for preventing and treating oral diseases, then basic oral hygiene is maintained, but they fail to provide long-term protection against tartar build-up, gingivitis, and periodontal disease
Solution Approach 1:
The patent creates a composite material system by combining bridged polycyclic compounds with antimicrobial agents (such as chlorhexidine, cetylpyridinium chloride, or essential oils) and dental care components (fluoride, abrasives, binders). This composite formulation provides both immediate antimicrobial action and long-term protection by forming a sustained-release coating on oral surfaces, addressing both ease of use and duration of protection.
4Reliability
If multiple pharmaceutically active agents are attached to bridged polycyclic compounds, then the intracellular drug amount is increased, but the complexity of the compound structure increases
Solution Approach 1:
The bridged polycyclic compounds serve as universal multi-functional platforms that can simultaneously attach multiple different pharmaceutically active agents through their available functional groups. The core structure provides a stable scaffold with standardized attachment points, allowing diverse drugs (antivirals, antibiotics, antifungals, anti-inflammatories) to be combined without increasing overall molecular complexity significantly, as the attachment chemistry follows predictable patterns.
Data Source
AI summary
A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an oral surface of a human such that an oral malady may be inhibited and/or ameliorated.